FindTrial
Sign In

Ovidrel Syringe 250 microgram Drug Use-Results Survey

Ovidrel Syringe 250 microgram Drug Use-Results Survey - Drug Use-Results Survey of Ovidrel

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000036930
Enrollment
320
Registered
2019-06-04
Start date
2017-09-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Merck Biopharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: For the indications of Ovidrel, which are ovulation induction and luteinization in anovulation or oligoovulation associated with hypothalamic-pituitary dysfunction and maturation of ovum and luteinization in assisted reproductive technology, patients who receive Ovidrel for the first time and give consent to participation in this survey. For self-injection at home, patients who received Ovidrel for the first time through self-injection at home.

Exclusion criteria

Exclusion criteria: Patients with contraindications in the package insert.

Design outcomes

Primary

MeasureTime frame
The incidence of adverse drug reactions and infections, the incidence of serious adverse events, and so on—

Countries

Japan

Contacts

Public ContactTatsuya Ogura

Merck Biopharma Co., Ltd. PMS Planning & Strategy, Medical Department

tatsuya.ogura@merckgroup.com03-6756-0750

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026